Compared with ATRA-CHT, the CHT-free Strategy of ATRA and ATO resulted in greater event-free survival in non-high risk APL in the APL0406 trial [8, 16, 17]. The gene discussed is SLC5A7; the disease is acute promyelocytic leukemia.